Abstract
The objective of the present study was to develop, evaluate and optimize a polymeric nanoparticle (NP) system containing Cxb for pulmonary delivery of Cxb in the treatment of lung cancer. NPs were prepared by the emulsion solvent diffusion and evaporation method using poly(D, L lactideglycolide) (PLGA). The size of NPs ranged from 153 to 192 nm and was affected by PLGA content, surfactant concentration and organic phase volume. Zeta potential of NPs (−4.5 to −8.6 mV) was more affected by PLGA content and organic phase volume. PLGA content was also the most effective factor on the entrapment efficiency and release rate of Cxb from NPs. The optimum formulation which obtained with 5 mg Cxb, 25 mg PLGA, 0.5% surfactant, 2.5% organic volume and 15 000 rpm showed release of Cxb within 30 h. The optimized formulation co-spray dried with lactose (hybrid microparticles) displayed desirable fine particle fraction, mass medium aerodynamic diameter, geometric standard deviation of 70.3%, 1.46% and 3.38%, respectively. Our results provide evidence for the potential of PLGA NPs for delivery of Cxb through inhalation as means to alleviate the cardiovascular risk of Cxb administration.
Declaration of interest
The authors wish to thank the Vice Chancellery of Isfahan University of Medical Sciences for financial support of this work under project No. 185134. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.